June 7, 2017 / 11:27 AM / 6 months ago

BRIEF-Arqule initiates early-stage trial of ARQ 092

June 7 (Reuters) - Arqule Inc

* Arqule announces first patient dosed in company sponsored phase 1/2 trial of akt inhibitor, ARQ 092, for rare overgrowth diseases

* Phase 1/2 trial with co’s akt inhibitor, arq 092, will enroll patients with overgrowth diseases driven by pi3k/akt1 pathway Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below